Cubist Pharma Cvr (CBSTZ) 0.63 $CBSTZ
Global Klebsiella Pneumoniae Infections Pipeline Review 2014 - Analysis of 12 Companies & 21 Drug Profiles
M2 - Thu Apr 17, 6:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/frwd77/klebsiella) has announced the addition of the "Klebsiella Pneumoniae Infections - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Klebsiella Pneumoniae Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Klebsiella Pneumoniae Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Klebsiella Pneumoniae Infections - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Klebsiella Pneumoniae Infections and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Klebsiella Pneumoniae Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Klebsiella Pneumoniae Infections pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Klebsiella Pneumoniae Infections - Companies Involved in Therapeutics Development - Dainippon Sumitomo Pharma Co., Ltd. - Melinta Therapeutics, Inc - Cubist Pharmaceuticals, Inc. - Pfizer Inc. - Soligenix, Inc. - FOB Synthesis, Inc. - Phico Therapeutics Ltd. - Trana Discovery, Inc. - Cantab Biopharmaceuticals Limited - Procarta Biosystems Ltd - Northern Antibiotics Oy - Arsanis Biosciences GmbH Drug Profiles - CB-618 - RX-04 - Drugs for Gram-Negative Nonsocomial Infections - CB-027 - SM-295291 - SM-369926 - SGX-942 - Small Moleule To Inhibit Lipopolysaccharide For Nosocomial Infections - Antimicrobial Compounds for Bacterial Infections - NAB-741 - NAB-7061 - Monoclonal Antibody For Klebsiella Pneumoniae Infections - IBN-1 - PMBN-fMLF - PMEN-fMLF - FSI-1686 - SASPject PT-3.X - RX-05 - Snare Antibacterial For Gram Negative Infections - Antibiotics For Hospital-Acquired Gram-Negative Bacterial Infections - MVX-506 For more information visit http://www.researchandmarkets.com/research/frwd77/klebsiella
Cubist to Announce First Quarter 2014 Financial Results on Tuesday, April 22, 2014
Business Wire - Tue Apr 15, 7:00AM CDT
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) will issue its first quarter 2014 financial results at 4:00 p.m. ET on Tuesday, April 22, 2014. In connection with this announcement, Cubist will host a conference call and live audio webcast presentation at 5:00 p.m. ET that same day to discuss its first quarter financial results, business activities, and financial outlook.
Cellceutix Reports 20 Percent Enrollment Completed in Phase 2b Trial of Brilacidin as Short-Course Therapy for ABSSSI
Marketwire - Mon Mar 31, 8:25AM CDT
Cellceutix Corporation (OTCQB: CTIX) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to provide shareholders an update on the status of the Company's clinical trial of its novel antibiotic Brilacidin as a treatment for Acute Bacterial Skin and Skin Structure Infections (ABSSSI). One month into the study, the trial has completed enrollment of approximately 20 percent of the total patients scheduled in the protocol.
Zacks Industry Outlook Highlights: Eli Lilly, AstraZeneca, Shire, Salix and Cubist Pharmaceuticals
PR Newswire - Thu Mar 27, 8:30AM CDT
Today, Zacks Equity Research discusses the Pharma & Biotech, including Eli Lilly (NYSE:LLY-Free Report), AstraZeneca (NYSE:AZN-Free Report), Shire (Nasdaq:SHPG-Free Report), Salix (Nasdaq:SLXP-Free Report) and Cubist Pharmaceuticals (Nasdaq:CBST-Free Report).
Avanir Pharmaceuticals names Dr Mark Corrigan to board
M2 - Thu Mar 20, 5:02AM CDT
Biopharmaceutical company Avanir Pharmaceuticals (NasdaqGS:AVNR) revealed on Wednesday the addition of Dr Mark Corrigan to its board of directors.
Cellceutix Enrolls First Patients in Phase 2b ABSSSI Clinical Trial
Marketwire - Wed Feb 26, 5:00AM CST
Cellceutix Corporation (OTCQB: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, announces today that the first patients have been enrolled and treated in the Company's Phase 2b clinical trial of Brilacidin in patients with Acute Bacterial Skin and Skin Structure Infection (ABSSSI).
Competitor Analysis: Clostridium Difficile Vaccines and Therapeutics
M2 - Tue Feb 18, 2:37AM CST
Research and Markets (http://www.researchandmarkets.com/research/kkvg3x/competitor) has announced the addition of the "Competitor Analysis: Clostridium Difficile Vaccines and Therapeutics" report to their offering. Clostridium difficile infections (CDI) are a major public health concern. CDI are becoming increasingly prevalent in hospitals, long-term and primary-care facilities, primarily in patients whose normal intestinal flora have been compromised by antibiotic treatment. CDI primary virulence mechanismis the production of two toxins, TcdA and TcdB, which glucosylate Rho-family GTPases, disrupt the actin cytoskeleton, and causing cytotoxicity and inflammation. The present Competitive Intelligence Report about prophylaxis and therapy of Clostridium difficile infections provides a competitor evaluation in the field of new molecules or microorganisms for prevention or treatment of Clostridium difficle infections as of January 2014. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report. The report includes a compilation of currently active projects in research and development of antibodies, proteins, peptides, vaccines, microorganisms and small molecules for prevention and treatment of Clostridium difficile infections. In addition, the report lists company-specific R&D pipelines of C. difficile vaccines and therapeutics. Competitor projects are listed in a tabular format providing information on: - Drug Codes, - Target / Mechanism of Action, - Class of Compound, - Company, - Product Category, - Indication, - R&D Stage and - additional comments with a hyperlink leading to the source of information. Key Topics Covered - C. difficile Vaccines - C. difficile Antibodies - C. difficile Antibiotics - C. difficile targeting Microorganisms - C. difficile Anti-Infectives - Corporate C. difficile Vaccines & Therapeutics R&D Pipelines Companies Mentioned - Actelion - AIMM Therapeutics - AmpliPhi Biosciences - Astellas Pharma - AstraZeneca (MedImmune) - Aviex Technologies - Biota Pharmaceuticals - Crestone - Cubist Pharmaceuticals - DaVolterra - Immuron - Merck - Novacta Therapeutics - Novartis - Pfizer - Prokarium - Rebiotix - Sanofi Pasteur - Seres Health - Shire (ViroPharma) - Stellar Biotechnologies - Summit - Synthetic Biologics - Valneva - VaxInnate - Venenum Biodesign For more information visit http://www.researchandmarkets.com/research/kkvg3x/competitor About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline Review, H2 2013 Report
M2 - Thu Feb 06, 2:49AM CST
Research and Markets (http://www.researchandmarkets.com/research/c57d4f/clostridium) has announced the addition of the "Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline Review, H2 2013" report to their offering. 'Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease). Scope - A snapshot of the global therapeutic scenario for Clostridium Difficile Infections (Clostridium Difficile Associated Disease). - A review of the Clostridium Difficile Infections (Clostridium Difficile Associated Disease) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Clostridium Difficile Infections (Clostridium Difficile Associated Disease) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Overview Therapeutics Development Late Stage Products Clinical Stage Products Early Stage Products Unknown Stage Products Assessment by Monotherapy Products Assessment by Combination Products Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Assessment by Therapeutic Class Drug Profiles Featured News & Press Releases Companies Mentioned Sequella, Inc. MedImmune, LLC Daiichi Sankyo Company, Limited AmpliPhi Biosciences Corporation Merck & Co., Inc. Novartis AG Cubist Pharmaceuticals, Inc. The Medicines Company Pfizer Inc. Ranbaxy Laboratories Limited ViroPharma Incorporated Paratek Pharmaceuticals, Inc. Oragenics, Inc. Immuron Limited Summit Corporation plc Novabiotics Ltd ImmunoBiology Ltd. Aquapharm Biodiscovery Limited Microbiotix, Inc. Synthetic Biologics, Inc. AIMM Therapeutics B.V. and many more.... For more information visit http://www.researchandmarkets.com/research/c5...lostridium About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Catabasis Announces Appointment of Kenneth M. Bate as Independent Director
PR Newswire - Tue Feb 04, 7:00AM CST
Catabasis Pharmaceuticals Inc. today announced the appointment of Kenneth M. Bate to its board of directors as an independent director. Mr. Bate is an experienced biotechnology executive having led companies at various stages of development. He currently is chairman of the board of Cubist Pharmaceuticals, Inc., and is a director of BioMarin Pharmaceuticals, AVEO Pharmaceuticals and TransMedics, Inc. Mr. Bate currently serves as an independent biotechnology industry consultant and previously has served as president and chief executive officer of Archemix Corp. and NitroMed Inc., chief financial officer of Millennium Pharmaceuticals Inc. and Biogen Inc., and co-founded JSB Partners LLC, a banking and advisory services firm for biopharmaceutical and life sciences companies. He holds an MBA from the Wharton School of the University of Pennsylvania and a BA from Williams College.
Hospital Acquired Pneumonia (HAP) - Pipeline Review, H2 2013 Research Report
M2 - Mon Feb 03, 2:25AM CST
Research and Markets (http://www.researchandmarkets.com/research/fg3mhf/hospital_acquired) has announced the addition of the "Hospital Acquired Pneumonia (HAP) - Pipeline Review, H2 2013" report to their offering. 'Hospital Acquired Pneumonia (HAP) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Hospital Acquired Pneumonia (HAP), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hospital Acquired Pneumonia (HAP). Scope - A snapshot of the global therapeutic scenario for Hospital Acquired Pneumonia (HAP). - A review of the Hospital Acquired Pneumonia (HAP) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Hospital Acquired Pneumonia (HAP) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned AstraZeneca PLC Cubist Pharmaceuticals, Inc. Basilea Pharmaceutica AG Aridis Pharmaceuticals LLC Tetraphase Pharmaceuticals Inc. Meiji Seika Pharma Co., Ltd. Biota Pharmaceuticals, Inc. Adenium Biotech ApS Melinta Therapeutics Inc. For more information visit http://www.researchandmarkets.com/research/fg...l_acquired About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Bacteremia - Pipeline Review, H2 2013 Report
M2 - Mon Jan 27, 2:14AM CST
Research and Markets (http://www.researchandmarkets.com/research/qv84kq/bacteremia) has announced the addition of the "Bacteremia - Pipeline Review, H2 2013" report to their offering. 'Bacteremia - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Bacteremia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bacteremia. Scope - A snapshot of the global therapeutic scenario for Bacteremia. - A review of the Bacteremia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Bacteremia pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Bacteremia. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Bacteremia pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Cubist Pharmaceuticals, Inc. Nabriva Therapeutics AG Cellceutix Corporation For more information visit http://www.researchandmarkets.com/research/qv84kq/bacteremia About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Unaudited Results, Partnerships, and Stock Price Movements - Research Report on Cubist, Novavax, Exelixis, BioCryst, and Foundation Medicine
PR Newswire - Thu Jan 16, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting Cubist Pharmaceuticals Inc. (NASDAQ: CBST), Novavax, Inc. (NASDAQ: NVAX), Exelixis, Inc. (NASDAQ: EXEL), BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX), and Foundation Medicine, Inc. (NASDAQ: FMI). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Technical Dossier: Theravance, Alkermes, Cubist Pharma, and TherapeuticsMD
PR Newswire - Wed Jan 08, 7:00AM CST
On Tuesday, January 07, 2014, the U.S. equity market finished on a positive note. The S&P 500 ended the day at 1,837.88, up 0.61%; the Dow Jones Industrial Average closed at 16,530.94, up 0.64%; and the NASDAQ Composite Index finished at 4,153.18, up 0.96%. The S&P 500 Health Care Sector Index gained 1.01% to close the session at 644.13; and the S&P 500 Biotechnology Industry Index closed at 2,766.71, up 0.72%. The S&P 500 Biotechnology Industry Index has gained 10.05% in the previous three months, outperforming the S&P 500, which has gained 9.65% during the same period. Additionally, the S&P 500 Pharmaceuticals Sub Industry Index closed at 491.51, up 0.94%. The major movers in the Health Care Sector included Theravance Inc. (NASDAQ: THRX), Alkermes PLC (NASDAQ: ALKS), Cubist Pharmaceuticals Inc. (NASDAQ: CBST), and TherapeuticsMD Inc. (NYSE MKT: TXMD). All these companies are tracked by AAAResearchReports.com. Free technical research on THRX, ALKS, CBST, and TXMD can be downloaded upon signing up at:
Clinical Study Updates, Collaborations, and Stock Price Updates - Research Report on Medtronic, Regeneron, Celldex, Cubist, and MannKind
PR Newswire - Tue Dec 31, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting Medtronic, Inc. (NYSE: MDT), Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), Celldex Therapeutics, Inc. (NASDAQ: CLDX), Cubist Pharmaceuticals Inc. (NASDAQ: CBST), and MannKind Corp. (NASDAQ: MNKD). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Regulatory Updates, Clinical Trial Results, and Stock Price Movements - Research Report on Johnson & Johnson, Cubist, Regeneron, Medtronic, and Jazz Pharmaceuticals
PR Newswire - Thu Dec 19, 7:00AM CST
Editor Note: For more information about this release, please scroll to bottom.
Cubist Statement on FDA Action on the Use of Antibiotics in Farm Animals
Business Wire - Thu Dec 12, 6:00PM CST
Cubist Pharmaceuticals issued the following statement today regarding the U.S. Food and Drug Administration's (FDA) new voluntary plan to phase out the use of certain antibiotics for enhanced food production.
Market Research: Infectitious Diarrhea - Pipeline Review, H2 2013
M2 - Thu Dec 12, 2:33AM CST
Research and Markets (http://www.researchandmarkets.com/research/hz35wk/infectitious) has announced the addition of the "Infectitious Diarrhea - Pipeline Review, H2 2013" report to their offering. 'Infectitious Diarrhea - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Infectitious Diarrhea, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Infectitious Diarrhea. Scope - A snapshot of the global therapeutic scenario for Infectitious Diarrhea. - A review of the Infectitious Diarrhea products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Infectitious Diarrhea pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Infectitious Diarrhea. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Infectitious Diarrhea pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Actelion Ltd Cubist Pharmaceuticals, Inc. Napo Pharmaceuticals, Inc. TheraCarb Inc. For more information visit http://www.researchandmarkets.com/research/hz...fectitious About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Skin And Skin Structure Infections (SSSI) Caused By Bacteria - Pipeline Review, H2 2013
M2 - Wed Dec 11, 2:50AM CST
Research and Markets (http://www.researchandmarkets.com/research/j32rt8/skin_and_skin) has announced the addition of the "Skin And Skin Structure Infections (SSSI) Caused By Bacteria - Pipeline Review, H2 2013" report to their offering. 'Skin And Skin Structure Infections (SSSI) Caused By Bacteria - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Skin And Skin Structure Infections (SSSI) Caused By Bacteria, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Skin And Skin Structure Infections (SSSI) Caused By Bacteria. Scope - A snapshot of the global therapeutic scenario for Skin And Skin Structure Infections (SSSI) Caused By Bacteria. - A review of the Skin And Skin Structure Infections (SSSI) Caused By Bacteria products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Skin And Skin Structure Infections (SSSI) Caused By Bacteria pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Skin And Skin Structure Infections (SSSI) Caused By Bacteria. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Skin And Skin Structure Infections (SSSI) Caused By Bacteria pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned GlaxoSmithKline plc Cubist Pharmaceuticals, Inc. Paratek Pharmaceuticals, Inc. Affinium Pharmaceuticals, Inc. MerLion Pharmaceuticals Pte Ltd Nabriva Therapeutics AG Cempra Pharmaceuticals, Inc. Tetraphase Pharmaceuticals Inc. Durata Therapeutics Inc. For more information visit http://www.researchandmarkets.com/research/j3...n_and_skin About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Respiratory Tract Infections - Pipeline Review, H2 2013
M2 - Tue Dec 10, 3:45AM CST
Research and Markets (http://www.researchandmarkets.com/research/665vfh/respiratory_tract) has announced the addition of the "Respiratory Tract Infections - Pipeline Review, H2 2013" report to their offering. The report provides an overview of the indication's therapeutic pipeline. It provides information on the therapeutic development for Respiratory Tract Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Respiratory Tract Infections. Scope - A snapshot of the global therapeutic scenario for Respiratory Tract Infections. - A review of the Respiratory Tract Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Respiratory Tract Infections pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - News and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Respiratory Tract Infections. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Respiratory Tract Infections pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned - Afexa Life Sciences - Cubist Pharmaceuticals - Daiichi Sankyo - Dongwha Pharm - GlaxoSmithKline - iBio. - Johnson & Johnson - Nanotherapeutics - Nippon Shinyaku - Novabiotics - Shionogi & Co. - Taisho Pharmaceutical For more information visit http://www.researchandmarkets.com/research/66...tory_tract About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
Orphan Drug Designations, Invitations to Investors Conferences, and Stock Price updates - Research Report on Teva, Cubist, Community Health Systems, Aegerion, and Air Methods
PR Newswire - Fri Dec 06, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting Teva Pharmaceutical Industries (NYSE: TEVA), Cubist Pharmaceuticals Inc. (NASDAQ: CBST), Community Health Systems, Inc. (NYSE: CHS), Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR), and Air Methods Corp. (NASDAQ: AIRM). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Global Klebsiella Pneumoniae Infections Pipeline Review 2014 - Analysis of 12 Companies & 21 Drug Profiles
M2 - Thu Apr 17, 6:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/frwd77/klebsiella) has announced the addition of the "Klebsiella Pneumoniae Infections - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Klebsiella Pneumoniae Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Klebsiella Pneumoniae Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Klebsiella Pneumoniae Infections - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Klebsiella Pneumoniae Infections and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Klebsiella Pneumoniae Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Klebsiella Pneumoniae Infections pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Klebsiella Pneumoniae Infections - Companies Involved in Therapeutics Development - Dainippon Sumitomo Pharma Co., Ltd. - Melinta Therapeutics, Inc - Cubist Pharmaceuticals, Inc. - Pfizer Inc. - Soligenix, Inc. - FOB Synthesis, Inc. - Phico Therapeutics Ltd. - Trana Discovery, Inc. - Cantab Biopharmaceuticals Limited - Procarta Biosystems Ltd - Northern Antibiotics Oy - Arsanis Biosciences GmbH Drug Profiles - CB-618 - RX-04 - Drugs for Gram-Negative Nonsocomial Infections - CB-027 - SM-295291 - SM-369926 - SGX-942 - Small Moleule To Inhibit Lipopolysaccharide For Nosocomial Infections - Antimicrobial Compounds for Bacterial Infections - NAB-741 - NAB-7061 - Monoclonal Antibody For Klebsiella Pneumoniae Infections - IBN-1 - PMBN-fMLF - PMEN-fMLF - FSI-1686 - SASPject PT-3.X - RX-05 - Snare Antibacterial For Gram Negative Infections - Antibiotics For Hospital-Acquired Gram-Negative Bacterial Infections - MVX-506 For more information visit http://www.researchandmarkets.com/research/frwd77/klebsiella
Cubist to Announce First Quarter 2014 Financial Results on Tuesday, April 22, 2014
Business Wire - Tue Apr 15, 7:00AM CDT
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) will issue its first quarter 2014 financial results at 4:00 p.m. ET on Tuesday, April 22, 2014. In connection with this announcement, Cubist will host a conference call and live audio webcast presentation at 5:00 p.m. ET that same day to discuss its first quarter financial results, business activities, and financial outlook.
Cellceutix Reports 20 Percent Enrollment Completed in Phase 2b Trial of Brilacidin as Short-Course Therapy for ABSSSI
Marketwire - Mon Mar 31, 8:25AM CDT
Cellceutix Corporation (OTCQB: CTIX) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to provide shareholders an update on the status of the Company's clinical trial of its novel antibiotic Brilacidin as a treatment for Acute Bacterial Skin and Skin Structure Infections (ABSSSI). One month into the study, the trial has completed enrollment of approximately 20 percent of the total patients scheduled in the protocol. Zacks Industry Outlook Highlights: Eli Lilly, AstraZeneca, Shire, Salix and Cubist Pharmaceuticals
PR Newswire - Thu Mar 27, 8:30AM CDT
Today, Zacks Equity Research discusses the Pharma & Biotech, including Eli Lilly (NYSE:LLY-Free Report), AstraZeneca (NYSE:AZN-Free Report), Shire (Nasdaq:SHPG-Free Report), Salix (Nasdaq:SLXP-Free Report) and Cubist Pharmaceuticals (Nasdaq:CBST-Free Report).
Avanir Pharmaceuticals names Dr Mark Corrigan to board
M2 - Thu Mar 20, 5:02AM CDT
Biopharmaceutical company Avanir Pharmaceuticals (NasdaqGS:AVNR) revealed on Wednesday the addition of Dr Mark Corrigan to its board of directors.
Cellceutix Enrolls First Patients in Phase 2b ABSSSI Clinical Trial
Marketwire - Wed Feb 26, 5:00AM CST
Cellceutix Corporation (OTCQB: CTIX) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, announces today that the first patients have been enrolled and treated in the Company's Phase 2b clinical trial of Brilacidin in patients with Acute Bacterial Skin and Skin Structure Infection (ABSSSI). Competitor Analysis: Clostridium Difficile Vaccines and Therapeutics
M2 - Tue Feb 18, 2:37AM CST
Research and Markets (http://www.researchandmarkets.com/research/kkvg3x/competitor) has announced the addition of the "Competitor Analysis: Clostridium Difficile Vaccines and Therapeutics" report to their offering. Clostridium difficile infections (CDI) are a major public health concern. CDI are becoming increasingly prevalent in hospitals, long-term and primary-care facilities, primarily in patients whose normal intestinal flora have been compromised by antibiotic treatment. CDI primary virulence mechanismis the production of two toxins, TcdA and TcdB, which glucosylate Rho-family GTPases, disrupt the actin cytoskeleton, and causing cytotoxicity and inflammation. The present Competitive Intelligence Report about prophylaxis and therapy of Clostridium difficile infections provides a competitor evaluation in the field of new molecules or microorganisms for prevention or treatment of Clostridium difficle infections as of January 2014. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report. The report includes a compilation of currently active projects in research and development of antibodies, proteins, peptides, vaccines, microorganisms and small molecules for prevention and treatment of Clostridium difficile infections. In addition, the report lists company-specific R&D pipelines of C. difficile vaccines and therapeutics. Competitor projects are listed in a tabular format providing information on: - Drug Codes, - Target / Mechanism of Action, - Class of Compound, - Company, - Product Category, - Indication, - R&D Stage and - additional comments with a hyperlink leading to the source of information. Key Topics Covered - C. difficile Vaccines - C. difficile Antibodies - C. difficile Antibiotics - C. difficile targeting Microorganisms - C. difficile Anti-Infectives - Corporate C. difficile Vaccines & Therapeutics R&D Pipelines Companies Mentioned - Actelion - AIMM Therapeutics - AmpliPhi Biosciences - Astellas Pharma - AstraZeneca (MedImmune) - Aviex Technologies - Biota Pharmaceuticals - Crestone - Cubist Pharmaceuticals - DaVolterra - Immuron - Merck - Novacta Therapeutics - Novartis - Pfizer - Prokarium - Rebiotix - Sanofi Pasteur - Seres Health - Shire (ViroPharma) - Stellar Biotechnologies - Summit - Synthetic Biologics - Valneva - VaxInnate - Venenum Biodesign For more information visit http://www.researchandmarkets.com/research/kkvg3x/competitor About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline Review, H2 2013 Report
M2 - Thu Feb 06, 2:49AM CST
Research and Markets (http://www.researchandmarkets.com/research/c57d4f/clostridium) has announced the addition of the "Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline Review, H2 2013" report to their offering. 'Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease). Scope - A snapshot of the global therapeutic scenario for Clostridium Difficile Infections (Clostridium Difficile Associated Disease). - A review of the Clostridium Difficile Infections (Clostridium Difficile Associated Disease) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Clostridium Difficile Infections (Clostridium Difficile Associated Disease) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Overview Therapeutics Development Late Stage Products Clinical Stage Products Early Stage Products Unknown Stage Products Assessment by Monotherapy Products Assessment by Combination Products Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Assessment by Therapeutic Class Drug Profiles Featured News & Press Releases Companies Mentioned Sequella, Inc. MedImmune, LLC Daiichi Sankyo Company, Limited AmpliPhi Biosciences Corporation Merck & Co., Inc. Novartis AG Cubist Pharmaceuticals, Inc. The Medicines Company Pfizer Inc. Ranbaxy Laboratories Limited ViroPharma Incorporated Paratek Pharmaceuticals, Inc. Oragenics, Inc. Immuron Limited Summit Corporation plc Novabiotics Ltd ImmunoBiology Ltd. Aquapharm Biodiscovery Limited Microbiotix, Inc. Synthetic Biologics, Inc. AIMM Therapeutics B.V. and many more.... For more information visit http://www.researchandmarkets.com/research/c5...lostridium About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Catabasis Announces Appointment of Kenneth M. Bate as Independent Director
PR Newswire - Tue Feb 04, 7:00AM CST
Catabasis Pharmaceuticals Inc. today announced the appointment of Kenneth M. Bate to its board of directors as an independent director. Mr. Bate is an experienced biotechnology executive having led companies at various stages of development. He currently is chairman of the board of Cubist Pharmaceuticals, Inc., and is a director of BioMarin Pharmaceuticals, AVEO Pharmaceuticals and TransMedics, Inc. Mr. Bate currently serves as an independent biotechnology industry consultant and previously has served as president and chief executive officer of Archemix Corp. and NitroMed Inc., chief financial officer of Millennium Pharmaceuticals Inc. and Biogen Inc., and co-founded JSB Partners LLC, a banking and advisory services firm for biopharmaceutical and life sciences companies. He holds an MBA from the Wharton School of the University of Pennsylvania and a BA from Williams College.
Hospital Acquired Pneumonia (HAP) - Pipeline Review, H2 2013 Research Report
M2 - Mon Feb 03, 2:25AM CST
Research and Markets (http://www.researchandmarkets.com/research/fg3mhf/hospital_acquired) has announced the addition of the "Hospital Acquired Pneumonia (HAP) - Pipeline Review, H2 2013" report to their offering. 'Hospital Acquired Pneumonia (HAP) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Hospital Acquired Pneumonia (HAP), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hospital Acquired Pneumonia (HAP). Scope - A snapshot of the global therapeutic scenario for Hospital Acquired Pneumonia (HAP). - A review of the Hospital Acquired Pneumonia (HAP) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Hospital Acquired Pneumonia (HAP) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned AstraZeneca PLC Cubist Pharmaceuticals, Inc. Basilea Pharmaceutica AG Aridis Pharmaceuticals LLC Tetraphase Pharmaceuticals Inc. Meiji Seika Pharma Co., Ltd. Biota Pharmaceuticals, Inc. Adenium Biotech ApS Melinta Therapeutics Inc. For more information visit http://www.researchandmarkets.com/research/fg...l_acquired About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Bacteremia - Pipeline Review, H2 2013 Report
M2 - Mon Jan 27, 2:14AM CST
Research and Markets (http://www.researchandmarkets.com/research/qv84kq/bacteremia) has announced the addition of the "Bacteremia - Pipeline Review, H2 2013" report to their offering. 'Bacteremia - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Bacteremia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bacteremia. Scope - A snapshot of the global therapeutic scenario for Bacteremia. - A review of the Bacteremia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Bacteremia pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Bacteremia. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Bacteremia pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Cubist Pharmaceuticals, Inc. Nabriva Therapeutics AG Cellceutix Corporation For more information visit http://www.researchandmarkets.com/research/qv84kq/bacteremia About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Unaudited Results, Partnerships, and Stock Price Movements - Research Report on Cubist, Novavax, Exelixis, BioCryst, and Foundation Medicine
PR Newswire - Thu Jan 16, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting Cubist Pharmaceuticals Inc. (NASDAQ: CBST), Novavax, Inc. (NASDAQ: NVAX), Exelixis, Inc. (NASDAQ: EXEL), BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX), and Foundation Medicine, Inc. (NASDAQ: FMI). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Technical Dossier: Theravance, Alkermes, Cubist Pharma, and TherapeuticsMD
PR Newswire - Wed Jan 08, 7:00AM CST
On Tuesday, January 07, 2014, the U.S. equity market finished on a positive note. The S&P 500 ended the day at 1,837.88, up 0.61%; the Dow Jones Industrial Average closed at 16,530.94, up 0.64%; and the NASDAQ Composite Index finished at 4,153.18, up 0.96%. The S&P 500 Health Care Sector Index gained 1.01% to close the session at 644.13; and the S&P 500 Biotechnology Industry Index closed at 2,766.71, up 0.72%. The S&P 500 Biotechnology Industry Index has gained 10.05% in the previous three months, outperforming the S&P 500, which has gained 9.65% during the same period. Additionally, the S&P 500 Pharmaceuticals Sub Industry Index closed at 491.51, up 0.94%. The major movers in the Health Care Sector included Theravance Inc. (NASDAQ: THRX), Alkermes PLC (NASDAQ: ALKS), Cubist Pharmaceuticals Inc. (NASDAQ: CBST), and TherapeuticsMD Inc. (NYSE MKT: TXMD). All these companies are tracked by AAAResearchReports.com. Free technical research on THRX, ALKS, CBST, and TXMD can be downloaded upon signing up at:
Clinical Study Updates, Collaborations, and Stock Price Updates - Research Report on Medtronic, Regeneron, Celldex, Cubist, and MannKind
PR Newswire - Tue Dec 31, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting Medtronic, Inc. (NYSE: MDT), Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), Celldex Therapeutics, Inc. (NASDAQ: CLDX), Cubist Pharmaceuticals Inc. (NASDAQ: CBST), and MannKind Corp. (NASDAQ: MNKD). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Regulatory Updates, Clinical Trial Results, and Stock Price Movements - Research Report on Johnson & Johnson, Cubist, Regeneron, Medtronic, and Jazz Pharmaceuticals
PR Newswire - Thu Dec 19, 7:00AM CST
Editor Note: For more information about this release, please scroll to bottom.
Cubist Statement on FDA Action on the Use of Antibiotics in Farm Animals
Business Wire - Thu Dec 12, 6:00PM CST
Cubist Pharmaceuticals issued the following statement today regarding the U.S. Food and Drug Administration's (FDA) new voluntary plan to phase out the use of certain antibiotics for enhanced food production.
Market Research: Infectitious Diarrhea - Pipeline Review, H2 2013
M2 - Thu Dec 12, 2:33AM CST
Research and Markets (http://www.researchandmarkets.com/research/hz35wk/infectitious) has announced the addition of the "Infectitious Diarrhea - Pipeline Review, H2 2013" report to their offering. 'Infectitious Diarrhea - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Infectitious Diarrhea, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Infectitious Diarrhea. Scope - A snapshot of the global therapeutic scenario for Infectitious Diarrhea. - A review of the Infectitious Diarrhea products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Infectitious Diarrhea pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Infectitious Diarrhea. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Infectitious Diarrhea pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Actelion Ltd Cubist Pharmaceuticals, Inc. Napo Pharmaceuticals, Inc. TheraCarb Inc. For more information visit http://www.researchandmarkets.com/research/hz...fectitious About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Skin And Skin Structure Infections (SSSI) Caused By Bacteria - Pipeline Review, H2 2013
M2 - Wed Dec 11, 2:50AM CST
Research and Markets (http://www.researchandmarkets.com/research/j32rt8/skin_and_skin) has announced the addition of the "Skin And Skin Structure Infections (SSSI) Caused By Bacteria - Pipeline Review, H2 2013" report to their offering. 'Skin And Skin Structure Infections (SSSI) Caused By Bacteria - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Skin And Skin Structure Infections (SSSI) Caused By Bacteria, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Skin And Skin Structure Infections (SSSI) Caused By Bacteria. Scope - A snapshot of the global therapeutic scenario for Skin And Skin Structure Infections (SSSI) Caused By Bacteria. - A review of the Skin And Skin Structure Infections (SSSI) Caused By Bacteria products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Skin And Skin Structure Infections (SSSI) Caused By Bacteria pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Skin And Skin Structure Infections (SSSI) Caused By Bacteria. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Skin And Skin Structure Infections (SSSI) Caused By Bacteria pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned GlaxoSmithKline plc Cubist Pharmaceuticals, Inc. Paratek Pharmaceuticals, Inc. Affinium Pharmaceuticals, Inc. MerLion Pharmaceuticals Pte Ltd Nabriva Therapeutics AG Cempra Pharmaceuticals, Inc. Tetraphase Pharmaceuticals Inc. Durata Therapeutics Inc. For more information visit http://www.researchandmarkets.com/research/j3...n_and_skin About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Respiratory Tract Infections - Pipeline Review, H2 2013
M2 - Tue Dec 10, 3:45AM CST
Research and Markets (http://www.researchandmarkets.com/research/665vfh/respiratory_tract) has announced the addition of the "Respiratory Tract Infections - Pipeline Review, H2 2013" report to their offering. The report provides an overview of the indication's therapeutic pipeline. It provides information on the therapeutic development for Respiratory Tract Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Respiratory Tract Infections. Scope - A snapshot of the global therapeutic scenario for Respiratory Tract Infections. - A review of the Respiratory Tract Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Respiratory Tract Infections pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - News and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Respiratory Tract Infections. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Respiratory Tract Infections pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned - Afexa Life Sciences - Cubist Pharmaceuticals - Daiichi Sankyo - Dongwha Pharm - GlaxoSmithKline - iBio. - Johnson & Johnson - Nanotherapeutics - Nippon Shinyaku - Novabiotics - Shionogi & Co. - Taisho Pharmaceutical For more information visit http://www.researchandmarkets.com/research/66...tory_tract About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
Orphan Drug Designations, Invitations to Investors Conferences, and Stock Price updates - Research Report on Teva, Cubist, Community Health Systems, Aegerion, and Air Methods
PR Newswire - Fri Dec 06, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting Teva Pharmaceutical Industries (NYSE: TEVA), Cubist Pharmaceuticals Inc. (NASDAQ: CBST), Community Health Systems, Inc. (NYSE: CHS), Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR), and Air Methods Corp. (NASDAQ: AIRM). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
